These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 22047505)

  • 1. Public perspectives about pharmacogenetic testing and managing ancillary findings.
    Haga SB; Tindall G; O'Daniel JM
    Genet Test Mol Biomarkers; 2012 Mar; 16(3):193-7. PubMed ID: 22047505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Professional perspectives about pharmacogenetic testing and managing ancillary findings.
    Haga SB; Tindall G; O'Daniel JM
    Genet Test Mol Biomarkers; 2012 Jan; 16(1):21-4. PubMed ID: 21770772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public attitudes toward ancillary information revealed by pharmacogenetic testing under limited information conditions.
    Haga SB; O'Daniel JM; Tindall GM; Lipkus IR; Agans R
    Genet Med; 2011 Aug; 13(8):723-8. PubMed ID: 21633294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Previous Genetic Counseling and Objective Numeracy on Accurate Interpretation of a Pharmacogenetics Test Report.
    Drelles K; Pilarski R; Manickam K; Shoben AB; Toland AE
    Public Health Genomics; 2021; 24(1-2):26-32. PubMed ID: 33445171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survey of genetic counselors and clinical geneticists' use and attitudes toward pharmacogenetic testing.
    Haga SB; O'Daniel JM; Tindall GM; Mills R; Lipkus IM; Agans R
    Clin Genet; 2012 Aug; 82(2):115-20. PubMed ID: 22283474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Collaborative Counseling Considerations for Pharmacogenomic Tests.
    Zierhut HA; Campbell CA; Mitchell AG; Lemke AA; Mills R; Bishop JR
    Pharmacotherapy; 2017 Sep; 37(9):990-999. PubMed ID: 28672074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survey of US public attitudes toward pharmacogenetic testing.
    Haga SB; O'Daniel JM; Tindall GM; Lipkus IR; Agans R
    Pharmacogenomics J; 2012 Jun; 12(3):197-204. PubMed ID: 21321582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing uptake of pharmacogenetic testing in a diverse patient population.
    O'Daniel J; Lucas J; Deverka P; Ermentrout D; Silvey G; Lobach DF; Haga SB
    Public Health Genomics; 2010; 13(1):48-54. PubMed ID: 19407441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Public perceptions of pharmacogenetics.
    Zhang SC; Bruce C; Hayden M; Rieder MJ
    Pediatrics; 2014 May; 133(5):e1258-67. PubMed ID: 24777223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient perspectives following pharmacogenomics results disclosure in an integrated health system.
    Lemke AA; Hulick PJ; Wake DT; Wang C; Sereika AW; Yu KD; Glaser NS; Dunnenberger HM
    Pharmacogenomics; 2018 Mar; 19(4):321-331. PubMed ID: 29469671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comfort with Pharmacogenetic Testing Amongst Pediatric Oncology Providers and Their Patients.
    Mowbray C; Turner J; Gai J; Jacobs S
    J Pediatr Hematol Oncol Nurs; 2022; 39(3):168-177. PubMed ID: 35467433
    [No Abstract]   [Full Text] [Related]  

  • 12. Consumers' views of pharmacogenetics--A qualitative study.
    Haddy CA; Ward HM; Angley MT; McKinnon RA
    Res Social Adm Pharm; 2010 Sep; 6(3):221-31. PubMed ID: 20813335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct-to-consumer pharmacogenomic testing is associated with increased physician utilisation.
    Bloss CS; Schork NJ; Topol EJ
    J Med Genet; 2014 Feb; 51(2):83-9. PubMed ID: 24343916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 3-I framework: a framework for developing public policies regarding pharmacogenomics (PGx) testing in Canada.
    Bashir NS; Ungar WJ
    Genome; 2015 Dec; 58(12):527-40. PubMed ID: 26623513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary care physicians' knowledge of and experience with pharmacogenetic testing.
    Haga SB; Burke W; Ginsburg GS; Mills R; Agans R
    Clin Genet; 2012 Oct; 82(4):388-94. PubMed ID: 22698141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Striking a balance in communicating pharmacogenetic test results: promoting comprehension and minimizing adverse psychological and behavioral response.
    Haga SB; Mills R; Bosworth H
    Patient Educ Couns; 2014 Oct; 97(1):10-5. PubMed ID: 24985359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Community pharmacists' experience with pharmacogenetic testing.
    Moaddeb J; Mills R; Haga SB
    J Am Pharm Assoc (2003); 2015; 55(6):587-594. PubMed ID: 26409205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ancillary risk information and pharmacogenetic tests: social and policy implications.
    Henrikson NB; Burke W; Veenstra DL
    Pharmacogenomics J; 2008 Apr; 8(2):85-9. PubMed ID: 17486108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of a personal CYP2D6 testing workshop on physician assistant student attitudes toward pharmacogenetics.
    O'Brien TJ; LeLacheur S; Ward C; Lee NH; Callier S; Harralson AF
    Pharmacogenomics; 2016 Mar; 17(4):341-52. PubMed ID: 26907849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physicians' Knowledge and Attitudes Regarding Point-of-Care Pharmacogenetic Testing: A Hospital-Based Cross-Sectional Study.
    Muflih S; Alshogran OY; Al-Azzam S; Al-Taani G; Khader YS
    Pharmgenomics Pers Med; 2021; 14():655-665. PubMed ID: 34103970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.